Clinical trial · Observational
CT Perfusion Parameters Predict Vascular Pattern in Hepatocellular Carcinoma
Computed Tomography Perfusion Parameters Predict Vascular Pattern in Hepatocellular Carcinoma: A Prospective Study
NCT04715321CI-TRIAL-00055706unknownClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Distinct vascular patterns (ECTC or Non-ECTC) of tumors plays an important role in tumor migration, metastasis and drug resistant in hepatocellular carcinoma (HCC). However, there is no non-invasive method to predict vascular pattern in clinical. In the present study, we prospectively assess CT perfusion parameters for evaluation of the vascular pattern in HCC.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Hepatocellular Carcinoma | Hepatocellular Carcinoma | ONTOLOGY_EXACT | 0.98 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| CT perfusion examination | Other | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- label
- Training cohort
- description
- HCC patients enrolled in our study underwent a perfusion CT examination before surgery . We used CT perfusion parameters to predict the vascular pattern of tumors.
- interventionNames
- Other: CT perfusion examination
- label
- Validation cohort
- description
- HCC patients who would undergo a perfusion CT examination before surgery will be enrolled in our study from January 15, 2021. We use CT perfusion parameters to predict the vascular pattern of tumors.
- interventionNames
- Other: CT perfusion examination
Primary outcomes (1)
- measure
- Predictive performance of CT perfusion
- timeFrame
- 6 months
- description
- The primary outcome of our study is to evaluate the sensitivity and specifity of CT perfusion in predicting vascular pattern of HCC
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
- Maximum age
- 75 Years
Show eligibility criteria text
Inclusion Criteria: 1. age over than 18 years old 2. tumor size of less than 5 cm 3. Child-Pugh A class liver function 4. an Eastern Cooperative Oncology Group performance status of 0 5. no previous treatment for HCC 6. pathological diagnosis of hepatocellular carcinoma 7. adequate organ function (white blood cell count ≥3.0 × 109/L, absolute neutrophil count ≥1.5 × 109/L, platelet count ≥75 × 109/L, aspartate transaminase and alanine transaminase≤5 × upper limit of the normal, creatinine clearance rate of ≤1.5 × upper limit of the normal, and left ventricular ejection ≥45%) Exclusion Criteria: 1. Patients who received antitumor therapy before recurrence, including radiotherapy, transarterial chemoembolization, tyrosine kinase inhibitor, and immune checkpoint inhibitor 2. a known medical history of HIV infection 3. pregnancy or breastfeeding 4. portal vein tumor thrombosis or hepatic vein thrombosis detected by any routine imaging modality, including ultrasonography, dynamic contrast CT and MRI 5. any evidence of tumor metastasis or prior recurrence 6. hepatic decompensation
References
Publications (0)
Data not yet available
No reference posted for this study.